Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma

Brentuximab vedotin is a monoclonal antibody that targets the CD30 antigen. It is indicated for the treatment of Hodgkin lymphoma. Hypersensitivity reactions have occurred during infusions of brentuximab vedotin, ranging from mild to severe. We report a case of a 46-year-old male with stage IV nodul...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalid, Sidra, Khalid, Aariez, Clark, Bernadette A, Daw, Hamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141060/
https://www.ncbi.nlm.nih.gov/pubmed/30237942
http://dx.doi.org/10.7759/cureus.2981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141060/
https://www.ncbi.nlm.nih.gov/pubmed/30237942
http://dx.doi.org/10.7759/cureus.2981

Ejemplares similares